Disclosure Of Intangible Assets [Text Block]

Egetis Therapeutics - Filing #5995613

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Disclosure of intangible assets [text block]
Research and development expense
1,462,000,000 SEK
1,940,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.